Literature DB >> 8541094

Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer.

A Goldhirsch, W C Wood, H J Senn, J H Glick, R D Gelber.   

Abstract

Entities:  

Mesh：

Year:  1995        PMID： 8541094     DOI： 10.1016/0959-8049(95)00479-3

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0959-8049            Impact factor:   9.162


× No keyword cloud information.
  11 in total

1.  miR-29b is an indicator of prognosis in breast cancer patients.

Authors:  Yoshiaki Shinden; Tomohiro Iguchi; Sayuri Akiyoshi; Hiroki Ueo; Masami Ueda; Hidenari Hirata; Shotaro Sakimura; Ryutaro Uchi; Yuki Takano; Hidetoshi Eguchi; Keishi Sugimachi; Yuko Kijima; Shoji Natsugoe; Koshi Mimori
Journal:  Mol Clin Oncol       Date:  2015-05-12

2.  Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer.

Authors:  J Arends; C Unger
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  Management of axillary lymph nodes in breast cancer: a national patterns of care study of 17,151 patients.

Authors:  D R Brenin; M Morrow; J Moughan; J B Owen; J F Wilson; D P Winchester
Journal:  Ann Surg       Date:  1999-11       Impact factor: 12.969

4.  Quality of adjuvant CMF chemotherapy for node-positive primary breast cancer: a population-based study.

Authors:  Michael Schaapveld; Elisabeth G E de Vries; Winette T A van der Graaf; Renée Otter; Pax H B Willemse
Journal:  J Cancer Res Clin Oncol       Date:  2004-07-16       Impact factor: 4.553

5.  Referral, receipt, and completion of chemotherapy in patients with early-stage breast cancer older than 65 years and at high risk of breast cancer recurrence.

Authors:  Diana S M Buist; Jessica Chubak; Marianne Prout; Marianne Ulcickas Yood; Jaclyn L F Bosco; Soe Soe Thwin; Heather Taffet Gold; Cynthia Owusu; Terry S Field; Virginia P Quinn; Feifei Wei; Rebecca A Silliman
Journal:  J Clin Oncol       Date:  2009-08-17       Impact factor: 44.544

6.  Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.

Authors:  F Joly; M Espié; M Marty; J F Héron; M Henry-Amar
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

Review 7.  Meeting highlights: the first korean breast cancer treatment consensus conference.

Authors:  Airi Han; Kyoung Eun Lee; Hae Kyung Lee; Yeon Hee Park; Jeryoung Kim; Sung-Won Kim; Kyung Hae Jung; Byung-Ho Son
Journal:  J Breast Cancer       Date:  2014-12-26       Impact factor: 3.588

8.  The adherence paradox: guideline deviations contribute to the increased 5-year survival of breast cancer patients.

Authors:  Christian O Jacke; Ute S Albert; Matthias Kalder
Journal:  BMC Cancer       Date:  2015-10-19       Impact factor: 4.430

9.  Iodine and doxorubicin, a good combination for mammary cancer treatment: antineoplastic adjuvancy, chemoresistance inhibition, and cardioprotection.

Authors:  Yunuen Alfaro; Guadalupe Delgado; Alfonso Cárabez; Brenda Anguiano; Carmen Aceves
Journal:  Mol Cancer       Date:  2013-05-24       Impact factor: 27.401

10.  Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study.

Authors:  Gwen Mhe Dackus; Natalie D Ter Hoeve; Mark Opdam; Willem Vreuls; Zsuzsanna Varga; Esther Koop; Stefan M Willems; Carolien Hm Van Deurzen; Emilie J Groen; Alicia Cordoba; Jos Bart; Antien L Mooyaart; Jan G van den Tweel; Vicky Zolota; Jelle Wesseling; Anna Sapino; Ewa Chmielik; Ales Ryska; Frederic Amant; Annegien Broeks; Ron Kerkhoven; Nikolas Stathonikos; Mitko Veta; Adri Voogd; Katarzyna Jozwiak; Michael Hauptmann; Marlous Hoogstraat; Marjanka K Schmidt; Gabe Sonke; Elsken van der Wall; Sabine Siesling; Paul J van Diest; Sabine C Linn
Journal:  BMJ Open       Date:  2017-11-14       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.